NCCN VERSION 2 2015

NCCN Guidelines Version 2.2015 Breast Cancer

NCCN Guidelines Index Breast Cancer Table of Contents Discussion

370. Wong TZ, Paulson EK, Nelson RC, et al. Practical approach to diagnostic CT combined with PET. AJR Am J Roentgenol 2007;188:622-629. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17312045 . 371. Hortobagyi GN, Singletary SE, Strom EA. Locally advanced breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. Philadelphia: Lippincott Williams & Wilkins; 2004. 372. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators. JAMA 1994;271:1587-1592. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8182811 . 373. Rosselli Del Turco M, Palli D, Cariddi A, et al. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. JAMA 1994;271:1593-1597. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7848404 . 374. Smith TJ, Davidson NE, Schapira DV, et al. American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol 1999;17:1080-1082. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10071303 . 375. Bast RC, Ravdin P, Hayes DF, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-1878. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11251019 . 376. Kirova YM, Stoppa-Lyonnet D, Savignoni A, et al. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer 2005;41:2304-2311. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16140006 .

377. Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004;22:2328-2335. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15197194 . 378. Pierce LJ, Levin AM, Rebbeck TR, et al. Ten-year multi- institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006;24:2437-2443. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16636335 . 379. ACOG committee opinion. No. 336: Tamoxifen and uterine cancer. Obstet Gynecol 2006;107:1475-1478. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16738185 . 380. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059-2063. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11145492 . 381. Boekhout AH, Vincent AD, Dalesio OB, et al. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2011;29:3862-3868. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21911720 . 382. Kaplan M, Mahon S, Cope D, et al. Putting evidence into practice: evidence-based interventions for hot flashes resulting from cancer therapies. Clin J Oncol Nurs 2011;15:149-157. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21444282 . 383. Bordeleau L, Pritchard KI, Loprinzi CL, et al. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol 2010;28:5147-5152. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21060031 .

Version 2.2015, 03/11/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. MS-94